Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

InterCure signs strategic service agreement with private company

XTL Biopharmaceuticals Ltd. today announced that InterCure Ltd., which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur.

25 Sep 2012

FDA Oncologic Drugs Advisory Committee to review Celgene’s pomalidomide NDA on Nov. 8

Celgene Corporation today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee will hold a review of the Company's new drug application (NDA) for pomalidomide at its meeting on November 8, 2012.

20 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance."

17 Sep 2012

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

Senesco Technologies, Inc. reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma.

14 Sep 2012

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.

11 Sep 2012

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.

7 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

NCCN announces new guidelines for patients with pancreatic Cancer

The National Comprehensive Cancer Network (NCCN), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

30 Aug 2012

Life-quality concerns for multiple myeloma survivors

Care of patients with multiple myeloma should not end with the achievement of long-term survival, suggests research indicating many experience poor health-related quality of life in the decade after diagnosis.

22 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

Researchers use small molecule compound to generate reversible birth control in male mice

The development of a male contraceptive pill has long proven to be elusive, but findings from a new study may point scientists in the right direction to making oral birth control for men a reality.

17 Aug 2012

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

InterCure signs strategic service agreement with private company

FDA Oncologic Drugs Advisory Committee to review Celgene’s pomalidomide NDA on Nov. 8

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Sorafenib could be effective against multiple myeloma

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

NCCN announces new guidelines for patients with pancreatic Cancer

Life-quality concerns for multiple myeloma survivors

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Mayo Clinic receives approval for construction of new building on Phoenix campus

Researchers use small molecule compound to generate reversible birth control in male mice

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in